This Article Full Text Full Text (PDF) RPHR Note Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haataja, L. Articles by Butler, P. C. Search for Related Content PubMed PubMed Citation Articles by Haataja, L. Articles by Butler, P. C.

Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis

Larry Hillblom Islet Research Center, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90024-2852

Correspondence: Address all correspondence and requests for reprints to: Peter C. Butler, Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, 900 Weyburn Place #A, Los Angeles, California 90024-2852. E-mail: pbutler{at}mednet.ucla.edu

Type 2 diabetes (T2DM) is characterized by insulin resistance, defective insulin secretion, loss of β-cell mass with increased β-cell apoptosis and islet amyloid. The islet amyloid is derived from islet amyloid polypeptide (IAPP, amylin), a protein coexpressed and cosecreted with insulin by pancreatic β-cells. In common with other amyloidogenic proteins, IAPP has the propensity to form membrane permeant toxic oligomers. Accumulating evidence suggests that these toxic oligomers, rather than the extracellular amyloid form of these proteins, are responsible for loss of neurons in neurodegenerative diseases. In this review we discuss emerging evidence to suggest that formation of intracellular IAPP oligomers may contribute to β-cell loss in T2DM. The accumulated evidence permits the amyloid hypothesis originally developed for neurodegenerative diseases to be reformulated as the toxic oligomer hypothesis. However, as in neurodegenerative diseases, it remains unclear exactly why amyloidogenic proteins form oligomers in vivo, what their exact structure is, and to what extent these oligomers play a primary or secondary role in the cytotoxicity in what are now often called unfolded protein diseases.

This article has been cited by other articles:

				J. Y. Park, H. S. No, Y. R. Ahn, S. H. Oh, Y. S. Kim, S. Y. Kim, K. T. Jang, S. W. Kim, J. H. Chung, Y. K. Min, et al. Pathologic Changes and Glucose Homeostasis According to Expression of Human Islet Amyloid Polypeptide in Type 2 Diabetic Patients J. Histochem. Cytochem., August 1, 2010; 58(8): 731 - 740. [Abstract] [Full Text] [PDF]

				T. Gurlo, S. Ryazantsev, C.-j. Huang, M. W. Yeh, H. A. Reber, O. J. Hines, T. D. O'Brien, C. G. Glabe, and P. C. Butler Evidence for Proteotoxicity in {beta} Cells in Type 2 Diabetes: Toxic Islet Amyloid Polypeptide Oligomers Form Intracellularly in the Secretory Pathway Am. J. Pathol., February 1, 2010; 176(2): 861 - 869. [Abstract] [Full Text] [PDF]

				C.-j. Huang, T. Gurlo, L. Haataja, S. Costes, M. Daval, S. Ryazantsev, X. Wu, A. E. Butler, and P. C. Butler Calcium-activated Calpain-2 Is a Mediator of Beta Cell Dysfunction and Apoptosis in Type 2 Diabetes J. Biol. Chem., January 1, 2010; 285(1): 339 - 348. [Abstract] [Full Text] [PDF]

				J. F. Aitken, K. M. Loomes, D. W. Scott, S. Reddy, A. R.J. Phillips, G. Prijic, C. Fernando, S. Zhang, R. Broadhurst, P. L'Huillier, et al. Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice Diabetes, January 1, 2010; 59(1): 161 - 171. [Abstract] [Full Text] [PDF]

				S. B. Widenmaier, Z. Ao, S.-J. Kim, G. Warnock, and C. H. S. McIntosh Suppression of p38 MAPK and JNK via Akt-mediated Inhibition of Apoptosis Signal-regulating Kinase 1 Constitutes a Core Component of the {beta}-Cell Pro-survival Effects of Glucose-dependent Insulinotropic Polypeptide J. Biol. Chem., October 30, 2009; 284(44): 30372 - 30382. [Abstract] [Full Text] [PDF]

				J. R. Cort, Z. Liu, G. M. Lee, K.N.L. Huggins, S. Janes, K. Prickett, and N. H. Andersen Solution state structures of human pancreatic amylin and pramlintide Protein Eng. Des. Sel., August 1, 2009; 22(8): 497 - 513. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes, April 1, 2009; 58(4): 773 - 795. [Full Text] [PDF]

				A. V. Matveyenko, T. Gurlo, M. Daval, A. E. Butler, and P. C. Butler Successful Versus Failed Adaptation to High-Fat Diet-Induced Insulin Resistance: The Role of IAPP-Induced {beta}-Cell Endoplasmic Reticulum Stress Diabetes, April 1, 2009; 58(4): 906 - 916. [Abstract] [Full Text] [PDF]

				W. Xu, C. Qiu, M. Gatz, N. L. Pedersen, B. Johansson, and L. Fratiglioni Mid- and Late-Life Diabetes in Relation to the Risk of Dementia: A Population-Based Twin Study Diabetes, January 1, 2009; 58(1): 71 - 77. [Abstract] [Full Text] [PDF]

				V. Poitout and R. P. Robertson Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction Endocr. Rev., May 1, 2008; 29(3): 351 - 366. [Abstract] [Full Text] [PDF]